Shattuck Labs develops antibody treatments for inflammatory and immune diseases, led by its DR3 blocking candidate SL-325. STTK reports earnings on Tue, Nov 10, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 12 | UBS | Initiated | Buy | |
| Oct 2 | Wedbush | Maintained | Buy | |
| Oct 2 | Needham | Target raised | Buy | |
| Sep 25 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 24 | Raymond James | Initiated | Buy |
Seasonality
How STTK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in STTK in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether STTK is in one of them and how their past STTK trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered STTK in an article yet. Here's the latest on the wider market.
About Shattuck Labs
Shattuck Labs is a biotechnology company based in Austin, Texas, that develops antibody treatments for inflammatory and immune diseases. Its lead candidate, SL-325, is designed to block the DR3 receptor, the only known receptor for the immune signaling molecule TL1A. The company is testing SL-325 in early clinical trials, with a planned focus on inflammatory bowel disease, and is also developing related antibodies. Its intended patients are people living with these conditions.
- Headquarters
- Austin, TX